Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERNESTO ALONSO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Clinical Neurophysiology

NPI
1396170601
CMS profile
630723
Location
LAKE CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$20,400.27

213 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 5 of 5; records 201–213 of 213 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERNESTO ALONSO

NPI 1396170601 · CMS profile ID 630723

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Clinical Neurophysiology

LAKE CITY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–213 of 213 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396170601?year=2025&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERNESTO ALONSO, NPI 1396170601, CMS profile ID 630723. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–213 of 213 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396170601?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ERNESTO ALONSO, NPI 1396170601, CMS profile ID 630723. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–213 of 213 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396170601?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ERNESTO ALONSO, NPI 1396170601, CMS profile ID 630723, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–213 of 213 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1396170601?year=2025&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

213 matching records · $20,400.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 213 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–213 of 213.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $11.1401/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201402710 CMS
ACADIA Pharmaceuticals Inc $17.2501/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247764648 CMS
Lundbeck LLC $5.5301/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251763242 CMS
Teva Pharmaceuticals USA, Inc. $27.5201/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247420014 CMS
KYOWA KIRIN, INC. $19.4201/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222072263 CMS
Alexion Pharmaceuticals, Inc. $18.7301/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202927866 CMS
Lundbeck LLC $9.1801/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251763240 CMS
PFIZER INC. $21.4001/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229918116 CMS
Novartis Pharmaceuticals Corporation $24.8801/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200183837 CMS
Lilly USA, LLC $20.5801/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186602382 CMS
Lundbeck LLC $20.2501/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251763238 CMS
PFIZER INC. $22.7301/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229922702 CMS
Eisai Inc. $24.0701/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244478858 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $961.55 46
PY2020 $1,976.65 149
PY2021 $57,607.11 262
PY2022 $62,597.69 278
PY2023 $35,653.25 237
PY2024 $31,938.44 228
PY2025 $20,400.27 213

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $269,184.50 132
PY2024 Principal investigator $381.48 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

132 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $2,673.00 12/03/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286488
Principal investigator 1 Ipsen Innovation $2,673.00 12/03/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286490
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293541
Principal investigator 1 Ipsen Innovation $2,234.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293543
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293545
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293547
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293549
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293551
Principal investigator 1 Ipsen Innovation $2,234.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293553
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293555
Principal investigator 1 Ipsen Innovation $4,353.75 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293557
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293559
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293561
Principal investigator 1 Ipsen Innovation $2,673.00 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293563
Principal investigator 1 Ipsen Innovation $2,470.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293565
Principal investigator 1 Ipsen Innovation $2,072.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293567
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293569
Principal investigator 1 Ipsen Innovation $2,072.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293571
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293573
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293575
Principal investigator 1 Ipsen Innovation $4,353.75 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293673
Principal investigator 1 Ipsen Innovation $2,673.00 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293675
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293677
Principal investigator 1 Ipsen Innovation $2,470.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293679
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293681
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293683
Principal investigator 1 Ipsen Innovation $2,072.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293685
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293687
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293689
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293691
Principal investigator 1 Ipsen Innovation $2,072.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293693
Principal investigator 1 Ipsen Innovation $2,234.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293695
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293697
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293699
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293701
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293703
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293705
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293707
Principal investigator 1 Ipsen Innovation $2,234.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293709
Principal investigator 1 Ipsen Innovation $4,353.75 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293711
Principal investigator 1 Ipsen Innovation $1,093.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293713
Principal investigator 1 Ipsen Innovation $4,353.75 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293715
Principal investigator 1 Ipsen Innovation $2,234.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293717
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293719
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293721
Principal investigator 1 Ipsen Innovation $2,234.25 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293723
Principal investigator 1 Ipsen Innovation $3,874.50 10/22/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293725
Principal investigator 1 Ipsen Innovation $1,093.50 09/29/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293493
Principal investigator 1 Ipsen Innovation $47.25 09/24/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293489
Principal investigator 1 Ipsen Innovation $1,046.25 09/24/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293505
Principal investigator 1 Ipsen Innovation $168.75 09/24/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293509
Principal investigator 1 Ipsen Innovation $47.25 09/24/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293517
Principal investigator 1 Ipsen Innovation $47.25 09/24/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293519
Principal investigator 1 Ipsen Innovation $47.25 09/24/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293521
Principal investigator 1 Ipsen Innovation $47.25 09/24/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293525
Principal investigator 1 Ipsen Innovation $47.25 09/24/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293527
Principal investigator 1 Ipsen Innovation $3,141.48 09/17/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293491
Principal investigator 1 Ipsen Innovation $47.25 09/17/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293495
Principal investigator 1 Ipsen Innovation $101.25 09/17/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293497
Principal investigator 1 Ipsen Innovation $375.00 09/17/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293501
Principal investigator 1 Ipsen Innovation $505.00 09/17/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293503
Principal investigator 1 Ipsen Innovation $236.25 09/17/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293507
Principal investigator 1 Ipsen Innovation $47.25 09/17/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293511
Principal investigator 1 Ipsen Innovation $168.75 09/17/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293515
Principal investigator 1 Ipsen Innovation $47.25 09/17/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293523
Principal investigator 1 Ipsen Innovation $750.00 09/15/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293499
Principal investigator 1 Ipsen Innovation $4,358.52 09/15/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293513
Principal investigator 1 Ipsen Innovation $126.00 08/20/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293443
Principal investigator 1 Ipsen Innovation $1,093.50 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293395
Principal investigator 1 Ipsen Innovation $2,234.25 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293397
Principal investigator 1 Ipsen Innovation $2,673.00 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293399
Principal investigator 1 Ipsen Innovation $4,353.75 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293401
Principal investigator 1 Ipsen Innovation $1,093.50 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293403
Principal investigator 1 Ipsen Innovation $2,072.25 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293405
Principal investigator 1 Ipsen Innovation $1,093.50 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293407
Principal investigator 1 Ipsen Innovation $2,234.25 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293409
Principal investigator 1 Ipsen Innovation $2,470.50 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293411
Principal investigator 1 Ipsen Innovation $1,093.50 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293413
Principal investigator 1 Ipsen Innovation $1,093.50 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293415
Principal investigator 1 Ipsen Innovation $1,093.50 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293417
Principal investigator 1 Ipsen Innovation $2,470.50 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293419
Principal investigator 1 Ipsen Innovation $1,093.50 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293421
Principal investigator 1 Ipsen Innovation $4,353.75 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293423
Principal investigator 1 Ipsen Innovation $2,072.25 07/30/2025 Non-covered Recipient Entity
M3 Wake Research
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293425
Principal investigator 1 Ipsen Innovation $180.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286458
Principal investigator 1 Ipsen Innovation $120.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286462
Principal investigator 1 Ipsen Innovation $240.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286468
Principal investigator 1 Ipsen Innovation $120.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286472
Principal investigator 1 Ipsen Innovation $240.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286474
Principal investigator 1 Ipsen Innovation $60.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286476
Principal investigator 1 Ipsen Innovation $60.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286478
Principal investigator 1 Ipsen Innovation $2,250.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286480
Principal investigator 1 Ipsen Innovation $60.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286484
Principal investigator 1 Ipsen Innovation $120.00 06/30/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286486
Principal investigator 1 Ipsen Innovation $3,989.25 06/27/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286460
Principal investigator 1 Ipsen Innovation $775.00 06/27/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286464
Principal investigator 1 Ipsen Innovation $3,989.25 06/27/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286466
Principal investigator 1 Ipsen Innovation $2,000.00 06/27/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286470
Principal investigator 1 Ipsen Innovation $8,000.00 06/27/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286482
Principal investigator 1 Ipsen Innovation $47.25 06/20/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286454
Principal investigator 1 Ipsen Innovation $125.00 06/20/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286456
Principal investigator 1 Ipsen Innovation $3,786.75 05/08/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286424
Principal investigator 1 Ipsen Innovation $1,741.50 05/08/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286430
Principal investigator 1 Ipsen Innovation $5,204.25 05/08/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286432
Principal investigator 1 Ipsen Innovation $4,725.00 05/08/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286434
Principal investigator 1 Ipsen Innovation $735.75 05/08/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286440
Principal investigator 1 Ipsen Innovation $47.25 05/07/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286422
Principal investigator 1 Ipsen Innovation $101.25 05/07/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286426
Principal investigator 1 Ipsen Innovation $54.00 05/07/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286428
Principal investigator 1 Ipsen Innovation $54.00 05/07/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286436
Principal investigator 1 Ipsen Innovation $47.25 05/07/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286438
Principal investigator 1 Ipsen Innovation $54.00 05/07/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286442
Principal investigator 1 Ipsen Innovation $2,673.00 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286382
Principal investigator 1 Ipsen Innovation $3,874.50 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286384
Principal investigator 1 Ipsen Innovation $2,072.25 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286388
Principal investigator 1 Ipsen Innovation $2,673.00 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286390
Principal investigator 1 Ipsen Innovation $4,353.75 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286392
Principal investigator 1 Ipsen Innovation $4,353.75 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286394
Principal investigator 1 Ipsen Innovation $3,874.50 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286396
Principal investigator 1 Ipsen Innovation $2,234.25 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286398
Principal investigator 1 Ipsen Innovation $2,234.25 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286400
Principal investigator 1 Ipsen Innovation $3,874.50 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286402
Principal investigator 1 Ipsen Innovation $2,072.25 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286404
Principal investigator 1 Ipsen Innovation $3,989.25 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286408
Principal investigator 1 Ipsen Innovation $1,093.50 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286412
Principal investigator 1 Ipsen Innovation $3,989.25 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286414
Principal investigator 1 Ipsen Innovation $1,093.50 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286416
Principal investigator 1 Ipsen Innovation $3,874.50 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286418
Principal investigator 1 Ipsen Innovation $3,989.25 04/28/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286420
Principal investigator 1 Ipsen Innovation $54.00 04/01/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286386
Principal investigator 1 Ipsen Innovation $3,989.25 04/01/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286406
Principal investigator 1 Ipsen Innovation $47.25 04/01/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCIATES
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184286410